Stan WongKoninklijke Philips ElectronicsPHGTOP PICKMay 26, 2017
This is a Netherlands name. Global health technology. Broadly speaking, he likes Europe. When you look at names in the euro zone, you want to look at those that are exporters.Because the euro has been low, these exporters can do very well from a currency standpoint. This continues to do well due to its continued cost cutting, restructuring and operational leverage measures. They are divesting their LED light bulbs. Consolidating their healthcare, personal care and consumer lifestyle divisions. Only trading at 10X enterprise value over EBITDA. Dividend yield of 2.4%. (Analysts’ price target is $35.77.)
Difficult time. Hasn't rationalized their business the way Siemens has. Needs to look at cost of capital of all businesses and get rid of non-core ones. No need to own. Instead, look at Siemens or US industrials.
It is on sale since there is a lawsuit regarding the CPAP machines which have been recalled. However the rest of the business is doing well. The risk is what the cost will be coming out of the lawsuit, but the risk/reward is OK. Buy for the longer term.
Fairly significant decline, but hasn't floored yet. There's never just one cockroach. Interesting franchise at the right price. Need some kind of catalyst before he'd get excited. Stay away for now.
No, it's not a European version of GE. Rather, PHG has done well, but their sleep apnea machine has gone into recall and attracted lawsuits. This is weighing on the stock, though long-term this is a good investment. Still happy to own it. But who knows how this or any lawsuit will end, and the overhang will continue over this stock.
Believes risk in Ukraine is regional and should not affect other parts of Europe.
Conflict in Ukraine is presenting buying opportunities.
Questions surrounding government spending on healthcare.
Good company that is good to hold long term.
Remember that the CAD is very strong, so European names may look down in your account because of the currency. Well run. If the turnaround is executed correctly, there could be significant upside from these levels. European stocks are trading down because of Ukraine. If you're underwater, you may just want to sell and move on.
They have grown into diagnostics equipment and connect care products. The stock is down due to a recall of their CPAP (sleep apnea) machines. He thinks this will create a good buying opportunity here that could double in the next 3-5 years. Yield 2.97% (Analysts’ price target is $55.13)
If you're in it, consider a longer term hold. If you don't have the patience for the headline risk, sell and move on. Lawsuit provides an excellent entry point, as with JNJ. Challenge is it sells big equipment, which has a long sales cycle. Attractively priced at these levels.
You want to buy it when it's on sale. A bit rich here. The diagnostics is an area of growth, but we'll have to wait and see. Hold, if you have a good entry point. Good quality company longer term. Not a buyer at this point.
(A Top Pick Dec 05/18, Up 31%) They used to make personal care products, but now make healthcare tech products and gaining market share. Managers have executed very well, transforming the company to higher-margin products.
Used to be in lighting. Now a premier provider of healthcare technology. Incredibly innovative, growing earnings at 15% rate. One of few great European tech companies. After restructuring, firing on all cylinders, and it's cheap. Yield is 2.5%. (Analysts’ price target is $46.63)
This is a Netherlands name. Global health technology. Broadly speaking, he likes Europe. When you look at names in the euro zone, you want to look at those that are exporters. Because the euro has been low, these exporters can do very well from a currency standpoint. This continues to do well due to its continued cost cutting, restructuring and operational leverage measures. They are divesting their LED light bulbs. Consolidating their healthcare, personal care and consumer lifestyle divisions. Only trading at 10X enterprise value over EBITDA. Dividend yield of 2.4%. (Analysts’ price target is $35.77.)